| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Clinical Biochemistry, Aarhus University Hospital [T. F. Ø.], and Department of Cytogenetics, Danish Cancer Society, Aarhus Amtssygehus, Tage Hansengade 2, DK 8000 Aarhus C [B. P.], and Department of Urology, Aarhus University Hospital, Skejby, DK 8200 Aarhus N [P. M., H. W.], Denmark
The molecular mechanism that in human bladder tumors leads to the loss of blood group ABO glycosyltransferase activity and, thereby, the loss of ABO antigens was investigated. In 15 tumors and 3 normal biopsies from blood group AB individuals and 7 tumors and 3 normal biopsies from blood group O individuals, mRNA was detected by a reverse transcription PCR (RT-PCR) assay, and the ABO blood group structure was determined by immunohistology. The RT-PCR spanned several introns in the ABO gene to exclude DNA contamination, and the RT-PCR product was shown to reflect the ABO gene message by dideoxy sequencing. The ABO mRNA was present in normal urothelium and low-grade tumors but disappeared from high grade tumors. This correlation to tumor grade was significant (P < 0.04). Immunohistochemistry with monoclonal anti-blood group antibodies showed a complete correlation between the presence of mRNA and the presence of AB carbohydrate structures on cell surfaces. In two urothelial cell lines, genotyped as A/- and A/A, growth stimulation with the cholera toxin B subunit led to a total loss of ABO mRNA, and epidermal growth factor stimulation had an identical effect on one of the cell lines. We conclude that the ABO glycosylation in normal and malignant urothelium is regulated at the mRNA level, and that a mechanism associated with cell proliferation may trigger down-regulation of ABO mRNA.
1 This work was supported by the Danish Cancer Research Fund; the Danish Cancer Society; the Blood Donor Foundation; the NOVO-Nordic Foundation; the Institute of Experimental Clinical Research, Aarhus University; the Clinical Oncology Trial Unit, Danish Cancer Society, Aarhus; and Legatstiftelsen Pedersholm.
2 To whom requests for reprints should be addressed, at Department of Clinical Biochemistry, Aarhus Amtssygehus, Tage Hansengade 2, DK 8000 Aarhus C, Denmark.
Received 9/26/95. Accepted 1/ 2/96.
This article has been cited by other articles:
![]() |
E. Dabelsteen and S. Gao ABO Blood-group Antigens in Oral Cancer Journal of Dental Research, January 1, 2005; 84(1): 21 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Olesen, T. Thykjaer, and T. F. Orntoft Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3 and TTK in human bladder cancer, screening for mutations and loss of heterozygosity Carcinogenesis, May 1, 2001; 22(5): 813 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Petretti, W Kemmner, B Schulze, and P M Schlag Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases Gut, March 1, 2000; 46(3): 359 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kominato, Y. Hata, H. Takizawa, T. Tsuchiya, J. Tsukada, and F.-i. Yamamoto Expression of Human Histo-blood Group ABO Genes Is Dependent upon DNA Methylation of the Promoter Region J. Biol. Chem., December 24, 1999; 274(52): 37240 - 37250. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kominato, T. Tsuchiya, N. Hata, H. Takizawa, and F.-i. Yamamoto Transcription of Human ABO Histo-blood Group Genes Is Dependent upon Binding of Transcription Factor CBF/NF-Y to Minisatellite Sequence J. Biol. Chem., October 10, 1997; 272(41): 25890 - 25898. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |